105 related articles for article (PubMed ID: 20807088)
1. Long-term response to maintenance treatment with rituximab in CD20(+) multiple myeloma.
Ohno H
Leuk Lymphoma; 2010 Nov; 51(11):2144-6. PubMed ID: 20807088
[No Abstract] [Full Text] [Related]
2. Pure red cell aplasia associated with CD20+ myeloma: complete remission with rituximab.
So CC; Choi WW; Kwong YL
Ann Hematol; 2013 Oct; 92(10):1425-6. PubMed ID: 23494205
[No Abstract] [Full Text] [Related]
3. Selective loss of lymphoid component simulating myeloma in lymphoplasmacytic lymphoma treated with rituximab.
O'Connor SR; Rana SK
Br J Haematol; 2013 May; 161(4):460. PubMed ID: 23530469
[No Abstract] [Full Text] [Related]
4. Reply to 'Rituximab in CD20 positive multiple myeloma' by P Moreau et al.
Greipp PT; Kapoor P; Morice WG; Witzig TE; Greipp PR
Leukemia; 2008 Jan; 22(1):214-5. PubMed ID: 17928885
[No Abstract] [Full Text] [Related]
5. Rituximab in CD20 positive multiple myeloma.
Bergua JM; Cabrera C; Arteta EG; Prieto J
Leukemia; 2008 May; 22(5):1082-3. PubMed ID: 17972949
[No Abstract] [Full Text] [Related]
6. Rituximab effective in a patient with refractory autoimmune haemolytic anaemia and CD20-negative multiple myeloma.
Hofer S; Hunziker S; Dirnhofer S; Ludwig C
Br J Haematol; 2003 Aug; 122(4):690-1. PubMed ID: 12899729
[No Abstract] [Full Text] [Related]
7. Reply to 'Rituximab activity in CD20-positive multiple myeloma'.
Gozzetti A; Fabbri A; Lazzi S; Bocchia M; Lauria F
Leukemia; 2008 May; 22(5):1083; author reply 1083-4. PubMed ID: 17972948
[No Abstract] [Full Text] [Related]
8. Rituximab in CD20 positive multiple myeloma.
Moreau P; Voillat L; Benboukher L; Mathiot C; Dumontet C; Robillard N; Hérault O; Garnache F; Garand R; Varoqueaux N; Avet-Loiseau H; Harousseau JL; Bataille R;
Leukemia; 2007 Apr; 21(4):835-6. PubMed ID: 17268523
[No Abstract] [Full Text] [Related]
9. Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy.
Korte W; Jost C; Cogliatti S; Hess U; Cerny T
Ann Oncol; 1999 Oct; 10(10):1249-50. PubMed ID: 10586345
[No Abstract] [Full Text] [Related]
10. CD20dim-positive T-cell large granular lymphocytic leukemia in a patient with concurrent hairy cell leukemia and plasma cell myeloma.
Xu X; Broome EH; Rashidi HH; South ST; Dell'aquila ML; Wang HY
Int J Clin Exp Pathol; 2010 Sep; 3(8):798-807. PubMed ID: 21151394
[TBL] [Abstract][Full Text] [Related]
11. Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma.
Zojer N; Kirchbacher K; Vesely M; Hübl W; Ludwig H
Leuk Lymphoma; 2006 Jun; 47(6):1103-9. PubMed ID: 16840202
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD20 monoclonal antibody therapy in multiple myeloma.
Kapoor P; Greipp PT; Morice WG; Rajkumar SV; Witzig TE; Greipp PR
Br J Haematol; 2008 Apr; 141(2):135-48. PubMed ID: 18318769
[TBL] [Abstract][Full Text] [Related]
13. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
14. Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma.
Baz R; Fanning S; Kunkel L; Gaballa S; Karam MA; Reed J; Kelly M; Hussein M
Leuk Lymphoma; 2007 Dec; 48(12):2338-44. PubMed ID: 18067008
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rituximab treatment in patients with progressive transformation of germinal centers after Hodgkin lymphoma in complete remission post-induction chemotherapy and radiotherapy.
Picardi M; Zeppa P; Ciancia G; Pettinato G; Grimaldi F; Fabbricini R; Mainolfi C; Pane F
Leuk Lymphoma; 2011 Nov; 52(11):2082-9. PubMed ID: 21663508
[TBL] [Abstract][Full Text] [Related]
16. The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia.
Le Garff-Tavernier M; Herbi L; de Romeuf C; Azar N; Roos-Weil D; Bonnemye P; Urbain R; Leblond V; Merle-Beral H; Vieillard V
Haematologica; 2015 Apr; 100(4):e147-51. PubMed ID: 25552707
[No Abstract] [Full Text] [Related]
17. Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression.
Shimada K; Tomita A; Saito S; Kiyoi H
Br J Haematol; 2014 Aug; 166(3):455-7. PubMed ID: 24673649
[No Abstract] [Full Text] [Related]
18. Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients.
Wyen C; Jensen B; Hentrich M; Siehl J; Sabranski M; Esser S; Gillor D; Müller M; Van Lunzen J; Wolf T; Bogner JR; Wasmuth JC; Christ H; Fätkenheuer G; Hoffmann C
AIDS; 2012 Feb; 26(4):457-64. PubMed ID: 22112600
[TBL] [Abstract][Full Text] [Related]
19. [Primary diffuse large B-cell lymphoma in uterine corpus: report of a case].
Dong W; Cao L; Wang DS
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):270-2. PubMed ID: 21616007
[No Abstract] [Full Text] [Related]
20. Waxing and waning intravascular large cell lymphoma with widespread organ infiltration.
Vos JM; Bordbar A; Vet RJ; Pals ST; Kater AP
Leuk Lymphoma; 2011 Apr; 52(4):705-8. PubMed ID: 21190427
[No Abstract] [Full Text] [Related]
[Next] [New Search]
